Oral · GLP-1 agonist
AZD0186
1 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
0
Sites
1
Countries
1
Endpoints
4
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
4
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05694741A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 | AZD0186 Prediabetes / glucose intolerance, Type 2 diabetes | Healthy volunteers | Ph 1 | Terminated | 1 | May 2023 | - |
Showing 1-1 of 1 trials